Item no. |
HY-16106A-1mg |
Manufacturer |
MedChem Express
|
CASRN |
1207456-00-5 |
Amount |
1 mg |
Quantity options |
100mg
10mM/1mL
10mg
1 mg
200mg
50mg
5 mg
|
Category |
|
Type |
Inhibitors |
Specific against |
other |
Purity |
98.36 |
Formula |
C19H14F2N6O |
Citations |
[1]Wang B, et al. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP- |
Smiles |
O=C1NN=C2C3=C1C=C(F)C=C3N[C@@H](C4=CC=C(F)C=C4)[C@@H]2C5=NC=NN5C |
ECLASS 5.1 |
30220300 |
ECLASS 6.1 |
30220300 |
ECLASS 8.0 |
32160605 |
ECLASS 9.0 |
32160605 |
ECLASS 10.0.1 |
32160490 |
ECLASS 10.1 |
32160490 |
ECLASS 11.0 |
32160490 |
UNSPSC |
12000000 |
Alias |
(8R,9S)-BMN-673; (8R,9S)-LT-673 |
Similar products |
(8R, 9S)-BMN-673, (8R, 9S)-LT-673 |
Available |
|
Product Description |
(8R, 9S)-Talazoparib ((8R, 9S)-BMN-673) is an enantiomer of Talazoparib. (8R, 9S)-Talazoparib is an PARP1 inhibitor, with an IC50 of 144 nM[1]. |
StorageTemperature |
-20°C, 3 years; 4°C, 2 years (Powder) |
Shipping |
Room Temperature |
Manufacturers Applications |
Cancer-programmed cell death |
MolecularWeight |
380.35 |
Clinical_Information |
No Development Reported |
Manufacturers Research Area |
Cancer |
Solubility |
DMSO : ≥ 50 mg/mL |
Manufacturers Target |
PARP |
Isoform |
PARP1 |
Pathway |
Cell Cycle/DNA Damage; Epigenetics |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.